Jeffrey W. Sherman - Aug 28, 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: Director
Signature: /s/ Beth Hecht, Attorney-in-Fact
Stock symbol: XERS
Transactions as of: Aug 28, 2025
Transactions value $: -$21,229
Form type: 4
Date filed: 8/29/2025, 05:21 PM
Previous filing: Jun 4, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
SHERMAN JEFFREY W	Director	C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO	/s/ Beth Hecht, Attorney-in-Fact	2025-08-29	0001230482

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Options Exercise	$313K	+47K	+21.94%	$6.66	261K	Aug 28, 2025	Direct
transaction	XERS	Common Stock	Sale	-$335K	-42.2K	-16.15%	$7.92	219K	Aug 28, 2025	Direct	F1
holding	XERS	Common Stock						5.4K	Aug 28, 2025	By: JEFFREY W SHERMAN LIVING TRUST U/A DTD 03/21/2001	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XERS	Stock Option (Right to Buy)	Options Exercise	$0	-47K	-100%	$0.00	0	Aug 28, 2025	Common Stock	47K	$6.66	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.920 to $7.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2	The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3	On October 1, 2016, the reporting person was granted an option to purchase shares of Strongbridge Biopharma plc ("Strongbridge") which were assumed by Issuer in connection with the acquisition of Strongbridge. The options vested in full on October 5, 2021.